Trials / Terminated
TerminatedNCT04624451
Evaluation of Intravenous Dalbavancin for Peritonitis
Evaluation of Intravenous Dalbavancin for Treatment of Peritonitis in Peritoneal Dialysis Patients
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 2 (actual)
- Sponsor
- University of Colorado, Denver · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dalbavancin | Dalbavancin 1500 mg intravenously x 1 dose |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2023-12-31
- Completion
- 2024-01-31
- First posted
- 2020-11-10
- Last updated
- 2024-05-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04624451. Inclusion in this directory is not an endorsement.